Home / Health / New Liver Therapy Shows Promise for Obesity
New Liver Therapy Shows Promise for Obesity
19 Jan
Summary
- Oral LXR agonist TLC-2716 shows safety and lipid-lowering in trials.
- TLC-2716 is now in Phase IIa trial for liver disease and hypertriglyceridemia.
- The drug aims to improve lipid parameters and reduce hepatic fat.
OrsoBio has reported promising Phase I clinical trial data for TLC-2716, an oral liver-targeted inverse agonist of Liver X Receptor (LXR). Published in Nature Medicine, the results in healthy volunteers highlighted TLC-2716's favorable safety profile and robust lipid-lowering effects. These findings align with preclinical research across various models, confirming effective liver-restricted LXR inhibition translation.
The therapy is currently undergoing evaluation in a Phase IIa trial focused on patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and severe hypertriglyceridemia (SHTG). These conditions impact over 80 million individuals in the United States. Final data from this ongoing trial is expected by mid-2026.
TLC-2716 works by modulating triglyceride and cholesterol homeostasis through mechanisms like suppressing hepatic de novo lipogenesis and enhancing lipoprotein clearance. The CEO noted its potential to address severe hypertriglyceridemia, elevated remnant cholesterol, and MASH, significantly reducing cardiovascular risks.
